Sk Zyryanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sk Zyryanov has a total of 500 co-authors. Here are the top co-authors by number of shared publications:
- Olga Igorevna Butranova
Department of General and Clinical Pharmacology, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia
39 shared publications - Elena A. Ushkalova
Peoples’ Friendship University of Russia
12 shared publications - Irina Lvovna Asetskaya
Department of General and Clinical Pharmacology, Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia
12 shared publications I. N. Dyakov
Scientific and Practical Center for Problems of Rational Pharmacotherapy and Pharmacoeconomics; 3 Mechnikov Research Institute of Vaccines and Serums
11 shared publications- Ilya N. Dyakov
Scientific and Practical Center for Problems of Rational Pharmacotherapy and Pharmacoeconomics; Mechnikov Research Institute of Vaccines and Serums
10 shared publications - Marina Vladimirovna Zhuravleva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
8 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Pharmacoeconomic impact of empagliflozin in patients with chronic kidney disease
Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of renal failure in patients with chronic kidney disease (CKD). Objective. To evaluate the pharmacoeconomic impact of empagliflozin in patients with CKD. Material and methods. The economic impact of empagliflozin treatment in adults with CKD was evaluated from the perspective of the Russian health care system under two scenarios: 1) treatment costs for the overall adult CKD population and 2) treatment costs per patient according to the estimated glomerular filtration rate (eGFR). A 10-year time horizon was modeled using R software. Both direct and indirect costs were included. Results. In a population of 18,116.4 thousand patients with CKD and a mean eGFR of 37.3±14.5 ml/min/1.73 m 2 , empagliflozin treatment was projected to reduce the disease burden by 11.95 trillion rubles (−12.1%) over 10 years. Direct costs were projected to decrease by 6.47 trillion rubles (9.8%). In addition, more than 2.4 million cases of disability were projected to be prevented (31.9% reduction), and 479,051 lives were projected to be saved (8.9% increase in survival). Initiating empagliflozin treatment at an eGFR of 37.3±14.5 ml/min/1.73 m 2 was projected to reduce direct costs per patient by 1.4 million rubles (58.9%) over 10 years. Total costs, including direct and indirect costs, were projected to decrease by more than 3.4 million rubles (77.6%). When treatment was initiated at an eGFR of 30.0 ml/min/1.73 m 2 , direct costs were projected to decrease by 5.5 million rubles (84.7%), and total costs by 13.0 million rubles (92.9%). Conclusion. The pharmacoeconomic analysis demonstrates that empagliflozin treatment in patients with CKD is economically justified and appropriate over a medium-term time horizon.
- 29 October 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Open AccessPharmacoeconomic impact of empagliflozin in patients with chronic kidney disease
Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of renal failure in patients with chronic kidney disease (CKD). Objective. To evaluate the pharmacoeconomic impact of empagliflozin in patients with CKD. Material and methods. The economic impact of empagliflozin treatment in adults with CKD was evaluated from the perspective of the Russian health care system under two scenarios: 1) treatment costs for the overall adult CKD population and 2) treatment costs per patient according to the estimated glomerular filtration rate (eGFR). A 10-year time horizon was modeled using R software. Both direct and indirect costs were included. Results. In a population of 18,116.4 thousand patients with CKD and a mean eGFR of 37.3±14.5 ml/min/1.73 m 2 , empagliflozin treatment was projected to reduce the disease burden by 11.95 trillion rubles (−12.1%) over 10 years. Direct costs were projected to decrease by 6.47 trillion rubles (9.8%). In addition, more than 2.4 million cases of disability were projected to be prevented (31.9% reduction), and 479,051 lives were projected to be saved (8.9% increase in survival). Initiating empagliflozin treatment at an eGFR of 37.3±14.5 ml/min/1.73 m 2 was projected to reduce direct costs per patient by 1.4 million rubles (58.9%) over 10 years. Total costs, including direct and indirect costs, were projected to decrease by more than 3.4 million rubles (77.6%). When treatment was initiated at an eGFR of 30.0 ml/min/1.73 m 2 , direct costs were projected to decrease by 5.5 million rubles (84.7%), and total costs by 13.0 million rubles (92.9%). Conclusion. The pharmacoeconomic analysis demonstrates that empagliflozin treatment in patients with CKD is economically justified and appropriate over a medium-term time horizon.
- Open Access
- 20 October 2026
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 28 (2) , 195-202
Biapenem use in pediatric patients: current state of knowledge
Biapenem, in combination with polymyxin and/or tigecycline, has promising potential in the treatment of severe infections in children, including infections caused by some difficult to treat resistant pathogens. However, biapenem is currently approved only for adult use, and its administration in pediatrics remains off-label. Available literature on pediatric use of biapenem predominantly dates back to the 1990s. There is a lack of data in Russian-language scientific literature regarding the use of biapenem in pediatric practice. This review is the first publication in Russian to systematize biapenem key pharmacokinetic and pharmacodynamic parameters, evaluate its potential for treating infections caused by resistant pathogens, describe optimal dosing regimens for children, and analyze its safety profile, including a comparison with data obtained from treating adults. Available pharmacokinetic data in children do not differ significantly from those in adults (Cmax of 24–65 mg/L, T1/2 of 1 hour), however, the volume of distribution, age-related metabolic changes, and dose adjustments for renal impairment in children remain uninvestigated. The most frequently reported dosing regimen in the literature is 6–12 mg/kg per dose or 15–30 mg/kg/day, whereas for the treatment of meningitis, doses of up to 40 mg/kg every 6 hours have been utilized. The drug demonstrates favorable tolerability and a lower incidence of adverse events compared to imipenem, with particular emphasis on its minimal neurotoxic potential relative to other carbapenems. Gaps in pharmacokinetic data for the pediatric population, the lack of reported cases of biapenem therapy for multidrug-resistant pathogens in children, and unresolved questions regarding dose adjustments in the context of rising resistance and altered pharmacokinetics in critically ill patients highlight the urgent need for modern prospective pharmacokinetic and clinical studies in children.
- 20 October 2026
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 28 (2) , 195-202
Open AccessBiapenem use in pediatric patients: current state of knowledge
Biapenem, in combination with polymyxin and/or tigecycline, has promising potential in the treatment of severe infections in children, including infections caused by some difficult to treat resistant pathogens. However, biapenem is currently approved only for adult use, and its administration in pediatrics remains off-label. Available literature on pediatric use of biapenem predominantly dates back to the 1990s. There is a lack of data in Russian-language scientific literature regarding the use of biapenem in pediatric practice. This review is the first publication in Russian to systematize biapenem key pharmacokinetic and pharmacodynamic parameters, evaluate its potential for treating infections caused by resistant pathogens, describe optimal dosing regimens for children, and analyze its safety profile, including a comparison with data obtained from treating adults. Available pharmacokinetic data in children do not differ significantly from those in adults (Cmax of 24–65 mg/L, T1/2 of 1 hour), however, the volume of distribution, age-related metabolic changes, and dose adjustments for renal impairment in children remain uninvestigated. The most frequently reported dosing regimen in the literature is 6–12 mg/kg per dose or 15–30 mg/kg/day, whereas for the treatment of meningitis, doses of up to 40 mg/kg every 6 hours have been utilized. The drug demonstrates favorable tolerability and a lower incidence of adverse events compared to imipenem, with particular emphasis on its minimal neurotoxic potential relative to other carbapenems. Gaps in pharmacokinetic data for the pediatric population, the lack of reported cases of biapenem therapy for multidrug-resistant pathogens in children, and unresolved questions regarding dose adjustments in the context of rising resistance and altered pharmacokinetics in critically ill patients highlight the urgent need for modern prospective pharmacokinetic and clinical studies in children.
- Open Access
- 16 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1029
Clinical and Microbiological Efficacy of the Antibacterial Drug Fluorothiazinone in the Treatment of Recurrent Cystitis in a Randomized Clinical Trial
Background/Objectives: New data on the pathogenesis of recurrent urinary tract infections (rUTIs) and the growing level of bacterial resistance to antibiotics require a revision of patient treatment strategies and a search for non-antibiotic approaches to the treatment and prevention of UTIs. The aim of this study was to investigate the clinical and microbiological efficacy of a new, non-traditional antibacterial drug, Fluorothiazinone (FT). Methods: We conducted an open-label, randomized, multicenter cohort clinical trial, phase III, at 12 hospitals in Moscow and St. Petersburg. A total of 280 patients were randomized into two groups in a 1:1 ratio to receive FT at a dose of 1200 mg/day for 14 days or furadonin at a dose of 400 mg/day for 7 days. Clinical and microbiological cures were assessed 7, 14, and 28 days after the start of therapy. Results: For the primary efficacy endpoint, clinical cure at day 28, the recovery rate was 91.7% in patients receiving FT and 92.8% in patients receiving furadonin, the hypothesis of non-inferiority of FT compared to the standard furadonin regimen was confirmed by two-sided 95% confidence intervals. The proportion of patients with clinical cure on days 7 and 14 also did not differ in the two groups. An assessment of microbiological eradication at all observation times in our study demonstrated that FT, whose mechanism of action is associated with the suppression of pathogen virulence, possesses antibacterial activity comparable to that of the antibiotic furadonin, leading to the eradication of pathogens causing rUTIs. The frequency of microbiological relapses after 28 days of treatment was 19.6% in the group receiving FT and 22.2% in the group receiving furadonin. Both study groups were comparable in the severity of adverse events (AEs). A definite relationship with the study drugs was identified for 1 (11.1%) AE after taking FT and 8 (88.9%) AEs after taking furadonin. Conclusions: Clinical trials in patients with recurrent cystitis have demonstrated the intrinsic antibacterial activity of FT, equal clinical and microbiological efficacy compared to first-line drugs for the treatment of recurrent cystitis, as well as a high level of safety, indicating the potential for the use of drugs with a new mechanism of action in the context of growing antibiotic resistance.
- 16 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1029
Open AccessClinical and Microbiological Efficacy of the Antibacterial Drug Fluorothiazinone in the Treatment of Recurrent Cystitis in a Randomized Clinical Trial
Background/Objectives: New data on the pathogenesis of recurrent urinary tract infections (rUTIs) and the growing level of bacterial resistance to antibiotics require a revision of patient treatment strategies and a search for non-antibiotic approaches to the treatment and prevention of UTIs. The aim of this study was to investigate the clinical and microbiological efficacy of a new, non-traditional antibacterial drug, Fluorothiazinone (FT). Methods: We conducted an open-label, randomized, multicenter cohort clinical trial, phase III, at 12 hospitals in Moscow and St. Petersburg. A total of 280 patients were randomized into two groups in a 1:1 ratio to receive FT at a dose of 1200 mg/day for 14 days or furadonin at a dose of 400 mg/day for 7 days. Clinical and microbiological cures were assessed 7, 14, and 28 days after the start of therapy. Results: For the primary efficacy endpoint, clinical cure at day 28, the recovery rate was 91.7% in patients receiving FT and 92.8% in patients receiving furadonin, the hypothesis of non-inferiority of FT compared to the standard furadonin regimen was confirmed by two-sided 95% confidence intervals. The proportion of patients with clinical cure on days 7 and 14 also did not differ in the two groups. An assessment of microbiological eradication at all observation times in our study demonstrated that FT, whose mechanism of action is associated with the suppression of pathogen virulence, possesses antibacterial activity comparable to that of the antibiotic furadonin, leading to the eradication of pathogens causing rUTIs. The frequency of microbiological relapses after 28 days of treatment was 19.6% in the group receiving FT and 22.2% in the group receiving furadonin. Both study groups were comparable in the severity of adverse events (AEs). A definite relationship with the study drugs was identified for 1 (11.1%) AE after taking FT and 8 (88.9%) AEs after taking furadonin. Conclusions: Clinical trials in patients with recurrent cystitis have demonstrated the intrinsic antibacterial activity of FT, equal clinical and microbiological efficacy compared to first-line drugs for the treatment of recurrent cystitis, as well as a high level of safety, indicating the potential for the use of drugs with a new mechanism of action in the context of growing antibiotic resistance.
- 14 October 2026
- Published by ECO-Vector LLC (Publications) in Russian Medicine
Tobacco Smoking and oncology: opportunities and barriers in providing medical and pharmacological care: A Review
Over the past decades, there has been an increase in cancer cases and related mortality. Smoking dependence on cancer patients is closely associated with their disease outcome. Continued smoking impacts therapy, relapse rates, postoperative complications, and survival, highlighting the importance of integrating smoking cessation assistance into oncological care. For this purpose, data from the available literature in the PubMed, Medline, and eLibrary databases were analyzed to identify current trends and barriers in the provision of medical care in oncology practice. It has been shown that the actual coverage of structured smoking cessation assistance (behavioral counseling, nicotine replacement therapy (NRT), and other pharmacological methods) remains limited, despite high reported motivation among some cancer patients. Similar barriers are observed in many countries, including Russia: a lack of time and expertise among oncologists, a lack of established routing protocols, limited availability and funding of NRT, and insufficient standardization of smoking status and pharmacotherapy use. Moreover, international meta-analyses confirm the effectiveness of NRT, Сytisine, and other smoking cessation methods and show that their combination with behavioral therapy also increases the chances of quitting. Adherence to smoking in cancer patients is a modifiable factor that requires healthcare intervention. In the Russian context, given the existing regulatory and clinical framework (Federal Law No. 15, clinical guidelines of the Russian Ministry of Health), there is a need for applied research in specific oncology centers aimed at assessing the actual practice of smoking cessation recommendations, prescribing pharmacotherapy, and identifying barriers encountered by physicians and patients. The collected data can be used to improve and personalize smoking cessation therapy for cancer patients, which will improve prognosis, increase the effectiveness of anticancer therapy, and reduce the pharmacoeconomic burden on the healthcare system.
- 14 October 2026
- Published by ECO-Vector LLC (Publications) in Russian Medicine
Tobacco Smoking and oncology: opportunities and barriers in providing medical and pharmacological care: A Review
Over the past decades, there has been an increase in cancer cases and related mortality. Smoking dependence on cancer patients is closely associated with their disease outcome. Continued smoking impacts therapy, relapse rates, postoperative complications, and survival, highlighting the importance of integrating smoking cessation assistance into oncological care. For this purpose, data from the available literature in the PubMed, Medline, and eLibrary databases were analyzed to identify current trends and barriers in the provision of medical care in oncology practice. It has been shown that the actual coverage of structured smoking cessation assistance (behavioral counseling, nicotine replacement therapy (NRT), and other pharmacological methods) remains limited, despite high reported motivation among some cancer patients. Similar barriers are observed in many countries, including Russia: a lack of time and expertise among oncologists, a lack of established routing protocols, limited availability and funding of NRT, and insufficient standardization of smoking status and pharmacotherapy use. Moreover, international meta-analyses confirm the effectiveness of NRT, Сytisine, and other smoking cessation methods and show that their combination with behavioral therapy also increases the chances of quitting. Adherence to smoking in cancer patients is a modifiable factor that requires healthcare intervention. In the Russian context, given the existing regulatory and clinical framework (Federal Law No. 15, clinical guidelines of the Russian Ministry of Health), there is a need for applied research in specific oncology centers aimed at assessing the actual practice of smoking cessation recommendations, prescribing pharmacotherapy, and identifying barriers encountered by physicians and patients. The collected data can be used to improve and personalize smoking cessation therapy for cancer patients, which will improve prognosis, increase the effectiveness of anticancer therapy, and reduce the pharmacoeconomic burden on the healthcare system.
- Open Access
- 9 October 2026
- Published by MDPI AG in Preprints.org
Clinical and Microbiological Efficacy of the Antibacterial Drug Fluorothiazinone in the Treatment of Recurrent Cystitis in a Randomized Clinical Trial
Background/Objectives: New data on the pathogenesis of recurrent urinary tract infections (rUTIs) and the growing level of bacterial resistance to antibiotics require a revision of patient treatment strategies and a search for non-antibiotic approaches to the treatment and prevention of UTIs. The aim of this study was to investigate the clinical and microbiological efficacy of a new, non-traditional antibacterial drug, Fluorothiazinone (FT). Methods: We conducted an open-label, randomized, multicenter cohort clinical trial, phase III, at 12 hospitals in Moscow and St. Petersburg. 280 patients were randomized into two groups in a 1:1 ratio to receive FT at a dose of 1200 mg/day for 14 days or furadoninat a dose of 400 mg/day for 7 days. Clinical and microbiological cure were assessed 7, 14 and 28 days after the start of therapy. Results: For the primary efficacy end-point, clinical cure at day 28, the recovery rate was 91.7% in patients receiving FT and 92.8% in patients receiving furadonin, the hypothesis of non-inferiority of FT compared to the standard furadonin regimen was confirmed by two-sided 95% confidence intervals. The proportion of patients with clinical cure on days 7 and 14 also did not differ in the two groups. An assessment of microbiological eradication at all observation times in our study demonstrated that FT, whose mechanism of action is associated with the suppression of pathogen virulence, possesses antibacterial activity comparable to that of the antibiotic furadonin leading to the eradication of pathogens causing rUTIs. The frequency of microbiological relapses after 28 days of treatment was 19.6% in the group receiving FT and 22.2% in the group receiving furadonin. Both study groups were comparable in the severity of adverse events (AEs). A definite relationship with the study drugs was identified for 1 (11.1%) AEs after taking FT and 8 (88.9%) AEs after taking furadonin.Conclusions: Clinical trials in patients with recurrent cystitis have demonstrated the intrinsic antibacterial activity of FT, equal clinical and microbiological efficacy compared to first-line drugs for the treatment of recurrent cystitis, as well as a high level of safety, indicating the potential for the use of drugs with a new mechanism of action in the context of growing antibiotic resistance.
- 9 October 2026
- Published by MDPI AG in Preprints.org
Open AccessClinical and Microbiological Efficacy of the Antibacterial Drug Fluorothiazinone in the Treatment of Recurrent Cystitis in a Randomized Clinical Trial
Background/Objectives: New data on the pathogenesis of recurrent urinary tract infections (rUTIs) and the growing level of bacterial resistance to antibiotics require a revision of patient treatment strategies and a search for non-antibiotic approaches to the treatment and prevention of UTIs. The aim of this study was to investigate the clinical and microbiological efficacy of a new, non-traditional antibacterial drug, Fluorothiazinone (FT). Methods: We conducted an open-label, randomized, multicenter cohort clinical trial, phase III, at 12 hospitals in Moscow and St. Petersburg. 280 patients were randomized into two groups in a 1:1 ratio to receive FT at a dose of 1200 mg/day for 14 days or furadoninat a dose of 400 mg/day for 7 days. Clinical and microbiological cure were assessed 7, 14 and 28 days after the start of therapy. Results: For the primary efficacy end-point, clinical cure at day 28, the recovery rate was 91.7% in patients receiving FT and 92.8% in patients receiving furadonin, the hypothesis of non-inferiority of FT compared to the standard furadonin regimen was confirmed by two-sided 95% confidence intervals. The proportion of patients with clinical cure on days 7 and 14 also did not differ in the two groups. An assessment of microbiological eradication at all observation times in our study demonstrated that FT, whose mechanism of action is associated with the suppression of pathogen virulence, possesses antibacterial activity comparable to that of the antibiotic furadonin leading to the eradication of pathogens causing rUTIs. The frequency of microbiological relapses after 28 days of treatment was 19.6% in the group receiving FT and 22.2% in the group receiving furadonin. Both study groups were comparable in the severity of adverse events (AEs). A definite relationship with the study drugs was identified for 1 (11.1%) AEs after taking FT and 8 (88.9%) AEs after taking furadonin.Conclusions: Clinical trials in patients with recurrent cystitis have demonstrated the intrinsic antibacterial activity of FT, equal clinical and microbiological efficacy compared to first-line drugs for the treatment of recurrent cystitis, as well as a high level of safety, indicating the potential for the use of drugs with a new mechanism of action in the context of growing antibiotic resistance.
- Open Access
- 30 September 2026
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 4-15
Pharmacoeconomic analysis of therapy for dystrophic and junctional types of inherited epidermolysis bullosa
Relevance . Inherited epidermolysis bullosa (EB) is a severe, chronic, systemic rare disease requiring lifelong therapy. In the Russian Federation, the unregistered drug beremagene geperpavec is used for the dystrophic type of EB. In 2025, a new drug Filsuvez® — a triterpene complex in gel formulation for topical application — was registered in the Russian Federation for both dystrophic and junctional types of EB. Objective . To compare budget impact of using the triterpene complex versus beremagene geperpavec in patients with EB in the Russian Federation. Methods . A budget impact analysis was performed from the healthcare perspective. Costs were based on the planned price of the triterpene complex and state procurement prices for beremagene geperpavec. Dressing costs were included. The patient population (patients under 18 years of age) was modelled using data from the Russian EB registry. Time horizon 3 years. Results . The budget impact analysis demonstrates a reduction in treatment costs of up to 14.5-fold when using the triterpene complex in comparison with beremagene geperpavec. In scenario expecting 30 % of patients with dystrophic EB receive triterpene complex therapy, the total savings over 3 years amount is to 17.0 billion RUB, at the same time both patients with dystrophic EB and additionally, due to cost saving, patients with junctional EB receive treatment. Conclusion . The use of the triterpene complex for dystrophic and junctional types of EB is pharmacoeconomically justified, significantly reduces the budget burden, and expands access to pathogenetic therapy also for patients with junctional EB.
- 30 September 2026
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 4-15
Open AccessPharmacoeconomic analysis of therapy for dystrophic and junctional types of inherited epidermolysis bullosa
Relevance . Inherited epidermolysis bullosa (EB) is a severe, chronic, systemic rare disease requiring lifelong therapy. In the Russian Federation, the unregistered drug beremagene geperpavec is used for the dystrophic type of EB. In 2025, a new drug Filsuvez® — a triterpene complex in gel formulation for topical application — was registered in the Russian Federation for both dystrophic and junctional types of EB. Objective . To compare budget impact of using the triterpene complex versus beremagene geperpavec in patients with EB in the Russian Federation. Methods . A budget impact analysis was performed from the healthcare perspective. Costs were based on the planned price of the triterpene complex and state procurement prices for beremagene geperpavec. Dressing costs were included. The patient population (patients under 18 years of age) was modelled using data from the Russian EB registry. Time horizon 3 years. Results . The budget impact analysis demonstrates a reduction in treatment costs of up to 14.5-fold when using the triterpene complex in comparison with beremagene geperpavec. In scenario expecting 30 % of patients with dystrophic EB receive triterpene complex therapy, the total savings over 3 years amount is to 17.0 billion RUB, at the same time both patients with dystrophic EB and additionally, due to cost saving, patients with junctional EB receive treatment. Conclusion . The use of the triterpene complex for dystrophic and junctional types of EB is pharmacoeconomically justified, significantly reduces the budget burden, and expands access to pathogenetic therapy also for patients with junctional EB.
- Open Access
- 12 August 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (4) , 620-633
Outpatient antimicrobial therapy prescribing patterns for respiratory tract infections in different regions of the Russian Federation
Outpatient antimicrobial therapy prescribing patterns for respiratory tract infections in different regions of the Russian Federation | Belkova | PULMONOLOGIYA Практика назначения антимикробных препаратов амбулаторным пациентам с инфекциями дыхательных путей в различных регионах Российской Федерации | Белькова | Пульмонология
- 12 August 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (4) , 620-633
Open AccessOutpatient antimicrobial therapy prescribing patterns for respiratory tract infections in different regions of the Russian Federation
Outpatient antimicrobial therapy prescribing patterns for respiratory tract infections in different regions of the Russian Federation | Belkova | PULMONOLOGIYA Практика назначения антимикробных препаратов амбулаторным пациентам с инфекциями дыхательных путей в различных регионах Российской Федерации | Белькова | Пульмонология
- Open Access
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 362-376
The relationship between the pharmacogenetics and pharmacokinetics of CFTR modulators in a population of children with cystic fibrosis
The triple combination of elexacaftor / tezacaftor / ivacaftor is one of the key tools for targeted pharmacotherapy of cystic fibrosis. In the pediatric population, its use may be accompanied by a variable therapeutic response, which may be due to age-related pharmacokinetic features, as well as the influence of genetic polymorphism of biotransformation enzymes. The aim. To analyze the pharmacokinetic parameters of elexacaftor, tezacaftor, ivacaftor, and lumacaftor in patients with cystic fibrosis, and to study the influence of various polymorphisms of cytochrome P450 genes ( CYP2C6*4, CYP2C19*2, CYP2D6*4 ) and the UGT1A1 gene on pharmacokinetics. Materials and Methods. The prospective single-center study included 32 patients with cystic fibrosis aged 6 to 18 years, of whom 29 received the combination of elexacaftor / tezacaftor / ivacaftor, and 3 received the dual combination of ivacaftor / lumacaftor. Analyte concentrations in plasma were determined by HPLC-MS/MS at five time points within 12 hours after drug administration. Molecular genetic analysis was performed on total DNA isolated from whole blood leukocytes using the phenol-chloroform extraction method. Results. Significant inter-individual variability in the pharmacokinetic parameters of all studied CFTR modulators was revealed. Normalized maximum concentrations of elexacaftor and ivacaftor were significantly higher in patients aged ≥ 12 years ( p = 0.027 and p = 0.046, respectively). Carriage of the CYP2C9*4 (GG) genotype, associated with slow metabolism, led to a statistically significant increase in the systemic exposure of elexacaftor ( p = 0.007) and ivacaftor ( p = 0.034). For the CYP2D6*4 (AA) genotype, a significant increase in elexacaftor concentration 3 hours after administration was found ( p = 0.041). Polymorphism of the UGT1A1 gene, including genotypes associated with Gilbert’s syndrome, did not have a significant effect on the total exposure of the studied drugs, while lower concentrations of tezacaftor and elexacaftor were noted at individual time points in carriers of the *28 allele. Conclusion. The pharmacokinetics of CFTR modulators in children are characterized by high variability and depend on age and the polymorphism of genes encoding CYP2C9 and CYP2D6 isoenzymes. The obtained data justify the need for further research to optimize dosing, taking into account genetic and demographic factors.
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 362-376
Open AccessThe relationship between the pharmacogenetics and pharmacokinetics of CFTR modulators in a population of children with cystic fibrosis
The triple combination of elexacaftor / tezacaftor / ivacaftor is one of the key tools for targeted pharmacotherapy of cystic fibrosis. In the pediatric population, its use may be accompanied by a variable therapeutic response, which may be due to age-related pharmacokinetic features, as well as the influence of genetic polymorphism of biotransformation enzymes. The aim. To analyze the pharmacokinetic parameters of elexacaftor, tezacaftor, ivacaftor, and lumacaftor in patients with cystic fibrosis, and to study the influence of various polymorphisms of cytochrome P450 genes ( CYP2C6*4, CYP2C19*2, CYP2D6*4 ) and the UGT1A1 gene on pharmacokinetics. Materials and Methods. The prospective single-center study included 32 patients with cystic fibrosis aged 6 to 18 years, of whom 29 received the combination of elexacaftor / tezacaftor / ivacaftor, and 3 received the dual combination of ivacaftor / lumacaftor. Analyte concentrations in plasma were determined by HPLC-MS/MS at five time points within 12 hours after drug administration. Molecular genetic analysis was performed on total DNA isolated from whole blood leukocytes using the phenol-chloroform extraction method. Results. Significant inter-individual variability in the pharmacokinetic parameters of all studied CFTR modulators was revealed. Normalized maximum concentrations of elexacaftor and ivacaftor were significantly higher in patients aged ≥ 12 years ( p = 0.027 and p = 0.046, respectively). Carriage of the CYP2C9*4 (GG) genotype, associated with slow metabolism, led to a statistically significant increase in the systemic exposure of elexacaftor ( p = 0.007) and ivacaftor ( p = 0.034). For the CYP2D6*4 (AA) genotype, a significant increase in elexacaftor concentration 3 hours after administration was found ( p = 0.041). Polymorphism of the UGT1A1 gene, including genotypes associated with Gilbert’s syndrome, did not have a significant effect on the total exposure of the studied drugs, while lower concentrations of tezacaftor and elexacaftor were noted at individual time points in carriers of the *28 allele. Conclusion. The pharmacokinetics of CFTR modulators in children are characterized by high variability and depend on age and the polymorphism of genes encoding CYP2C9 and CYP2D6 isoenzymes. The obtained data justify the need for further research to optimize dosing, taking into account genetic and demographic factors.
- Open Access
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 423-438
Cefodizime: safety profile in patients with comorbidities
The aim. To evaluate the safety profile of cefodizime in comparison with ceftriaxone and amoxicillin/clavulanic acid based on an analysis of current literature data. Materials and methods. A literature search was conducted among randomized controlled trials, cohort studies, meta-analyses, and clinical guidelines for the period from 2021 to 2026 in the PubMed database. Results . The analysis of publications and one clinical guideline revealed that the safety profile of cefodizime in comorbid patients is more favorable compared to ceftriaxone and amoxicillin / clavulanic acid. The use of ceftriaxone is associated with a dose-dependent and duration-dependent risk of developing biliary pseudolithiasis, cholestatic hepatitis, nephrolithiasis, and crystalluria, especially in patients with risk factors such as decompensated comorbidities, dehydration, starvation, and polypharmacy. Amoxicillin/clavulanic acid remains one of the leading causes of drug-induced liver injury, including cholestatic forms, and also demonstrates clinically significant interactions with vitamin K antagonists and direct oral anticoagulants. No convincing data on hepatotoxicity or nephrotoxicity or clinically significant interactions with oral anticoagulants were found for cefodizime, including in patients with hepatobiliary and urinary system pathology. However, the limited volume of clinical studies requires further investigation of its safety in larger cohorts. Conclusion . Cefodizime, ceftriaxone, and amoxicillin / clavulanic acid are effective in comorbid patients; however, their safety profiles differ. Cefodizime is characterized by a lack of data on hepatotoxicity and nephrotoxicity and does not demonstrate clinically significant drug interactions with oral anticoagulants, unlike ceftriaxone and amoxicillin / clavulanic acid. At the same time, the limited number of clinical studies on cefodizime requires further investigation of its safety profile in larger cohorts of comorbid patients.
- 20 July 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (4) , 423-438
Open AccessCefodizime: safety profile in patients with comorbidities
The aim. To evaluate the safety profile of cefodizime in comparison with ceftriaxone and amoxicillin/clavulanic acid based on an analysis of current literature data. Materials and methods. A literature search was conducted among randomized controlled trials, cohort studies, meta-analyses, and clinical guidelines for the period from 2021 to 2026 in the PubMed database. Results . The analysis of publications and one clinical guideline revealed that the safety profile of cefodizime in comorbid patients is more favorable compared to ceftriaxone and amoxicillin / clavulanic acid. The use of ceftriaxone is associated with a dose-dependent and duration-dependent risk of developing biliary pseudolithiasis, cholestatic hepatitis, nephrolithiasis, and crystalluria, especially in patients with risk factors such as decompensated comorbidities, dehydration, starvation, and polypharmacy. Amoxicillin/clavulanic acid remains one of the leading causes of drug-induced liver injury, including cholestatic forms, and also demonstrates clinically significant interactions with vitamin K antagonists and direct oral anticoagulants. No convincing data on hepatotoxicity or nephrotoxicity or clinically significant interactions with oral anticoagulants were found for cefodizime, including in patients with hepatobiliary and urinary system pathology. However, the limited volume of clinical studies requires further investigation of its safety in larger cohorts. Conclusion . Cefodizime, ceftriaxone, and amoxicillin / clavulanic acid are effective in comorbid patients; however, their safety profiles differ. Cefodizime is characterized by a lack of data on hepatotoxicity and nephrotoxicity and does not demonstrate clinically significant drug interactions with oral anticoagulants, unlike ceftriaxone and amoxicillin / clavulanic acid. At the same time, the limited number of clinical studies on cefodizime requires further investigation of its safety profile in larger cohorts of comorbid patients.
- 8 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (6) , 48-57
Resolution of the Expert Council on the Rational Management of Patients with Diabetic Sensorimotor Polyneuropathy and Neuropathic Pain
Diabetic distal symmetric sensorimotor polyneuropathy (DPN) represents one of the most prevalent and clinically significant complications associated with diabetes mellitus (DM). The painful variant of this condition substantially diminishes the quality of life for affected individuals, is associated with sleep disorders, anxiety, and depression, and encompasses an increased risk of adverse outcomes. In real-world practice, reliance solely on screening questionnaires without neurological examinations can lead to the underdiagnosis of DPN, especially in its painless form, and the overdiagnosis of neuropathic pain. Objective. To articulate a consensus expert position regarding the rational diagnosis, routing, and treatment of patients with distal polyneuropathy and neuropathic pain across various levels of medical care. Materials and methods. The expert council conducted a thorough analysis of contemporary clinical guidelines, international consensus documents, the scientific literature, and the practical challenges associated with managing patients with diabetic polyneuropathy in both primary and specialized medical care settings. Results. The council identified key levels of patient referral, including primary health care, consultation with a neurologist and/or endocrinologist, and access to specialized pain management centers. A practice-oriented diagnostic algorithm for primary care is proposed that encompasses a targeted collection of patient complaints, assessment of symptomatology, evaluation of tactile, vibration, and pain sensitivity, and assessment of tendon reflexes. Clear indications for specialist referral, criteria for initiating therapy, treatment objectives for the painful variant of DPN, and strategies for assessing treatment effectiveness have been established. The successful implementation of these recommended approaches requires the development of a regulatory framework for patient routing, the introduction of concise clinical algorithms, the initiation of educational programs for primary care physicians, and the assurance of the availability of pharmacological therapy. Conclusions. Enhancing the quality of care for patients with distal polyneuropathy can be achieved through a strategic combination of organizational, educational, clinical, and methodological initiatives that facilitate early diagnosis and appropriate treatment.
- 8 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (6) , 48-57
Resolution of the Expert Council on the Rational Management of Patients with Diabetic Sensorimotor Polyneuropathy and Neuropathic Pain
Diabetic distal symmetric sensorimotor polyneuropathy (DPN) represents one of the most prevalent and clinically significant complications associated with diabetes mellitus (DM). The painful variant of this condition substantially diminishes the quality of life for affected individuals, is associated with sleep disorders, anxiety, and depression, and encompasses an increased risk of adverse outcomes. In real-world practice, reliance solely on screening questionnaires without neurological examinations can lead to the underdiagnosis of DPN, especially in its painless form, and the overdiagnosis of neuropathic pain. Objective. To articulate a consensus expert position regarding the rational diagnosis, routing, and treatment of patients with distal polyneuropathy and neuropathic pain across various levels of medical care. Materials and methods. The expert council conducted a thorough analysis of contemporary clinical guidelines, international consensus documents, the scientific literature, and the practical challenges associated with managing patients with diabetic polyneuropathy in both primary and specialized medical care settings. Results. The council identified key levels of patient referral, including primary health care, consultation with a neurologist and/or endocrinologist, and access to specialized pain management centers. A practice-oriented diagnostic algorithm for primary care is proposed that encompasses a targeted collection of patient complaints, assessment of symptomatology, evaluation of tactile, vibration, and pain sensitivity, and assessment of tendon reflexes. Clear indications for specialist referral, criteria for initiating therapy, treatment objectives for the painful variant of DPN, and strategies for assessing treatment effectiveness have been established. The successful implementation of these recommended approaches requires the development of a regulatory framework for patient routing, the introduction of concise clinical algorithms, the initiation of educational programs for primary care physicians, and the assurance of the availability of pharmacological therapy. Conclusions. Enhancing the quality of care for patients with distal polyneuropathy can be achieved through a strategic combination of organizational, educational, clinical, and methodological initiatives that facilitate early diagnosis and appropriate treatment.